Precision BioSciences prices $125M stock offering to fund gene-editing trials
What's the deal? Precision BioSciences (Nasdaq: DTIL) priced a $125 million underwritten offering of common stock and pre-funded warrants on November 5, 2026. The clinical-stage gene-editing company sold 10,235,077 shares at $7.75 each, plus pre-funded warrants for a further 5,893,964 shares.
Who's in? The round drew new and existing investors, including First Light Asset ManagementDealroom has a profile for this one. Try Dealroom →, MPM BioImpactDealroom has a profile for this one. Try Dealroom →, Bleichroeder LP, Lynx1 Capital ManagementDealroom has a profile for this one. Try Dealroom →, Readout CapitalDealroom has a profile for this one. Try Dealroom →, aberdeenDealroom has a profile for this one. Try Dealroom → Investments, and Driehaus Capital ManagementDealroom has a profile for this one. Try Dealroom →. TD Cowen and Guggenheim SecuritiesDealroom has a profile for this one. Try Dealroom → acted as joint book-running managers.
What's the endgame? Precision uses its proprietary ARCUS platform to develop in vivo gene-editing therapies for diseases with few treatment options. The company will spend the net proceeds on research and development of two lead programmes: PBGENE-HBV, for chronic hepatitis B, and PBGENE-DMD, for Duchenne muscular dystrophy.
Why now? The raise follows a run of clinical milestones. Precision dosed its first PBGENE-DMD patient in the Phase 1/2 FUNCTION-DMD study, and an independent safety board cleared further dosing after the patient completed eight weeks with no serious adverse events. The company also scheduled a late-breaking presentation of PBGENE-HBV data at the AASLD Liver Meeting on November 8.
The money math. Precision reported a cash balance of $108 million as of September 30, 2026, which it said gives runway through 2028. The new offering, which was expected to close on or about November 6, strengthens that position ahead of multiple data readouts from both programmes.
The signal: At $125 million, the offering ranks in the upper tier of recent biotech raises by size — a sign that specialist life-sciences investors remain willing to back clinical-stage gene editing when early safety data holds up.
Read more: finance.minyanville.com
Image credit: Precision BioSciences
